姓名：张海鹏
职称：教授，博士生导师
联系邮箱：zhanghp@smu.edu.cn
主要招生方向：药理学、工业药学
个人简介
广东省杰青获得者，珠江科技新星。张海鹏教授专注于溶瘤病毒疗法的应用基础研究，以通讯或第一作者在Science Translational Medicine、Nature Communications（两篇）、PNAS（两篇）、Cell Reports等国际权威杂志发表论文12篇，相关学术成果被《Nature Reviews》专题评述。作为主要发明人授权中国专利6项，国际专利3项，其中一项专利获2022年度中国专利银奖。
目前担任中国药理学会抗炎免疫药理学专业委员会委员、中国药理学会临床药理学专业委员会青年委员和中国药理学会生化与分子药理学专业委员会青年委员；《Cell Reports Medicine》、《Acta Pharmacologica Sinica》、《Clinical and Translational Medicine》和《Advanced Healthcare Materials》等期刊审稿人。
学习经历
中山大学 博士（药理学） 2009.09-2014.06
山东大学 学士（药 学） 2005.09-2009.06
工作经历
南方医科大学药学院 教授，博导 2024.04-至今
暨南大学基础医学院 教授，博导 2018.04-2024.03
中山大学 博士后 2014.09-2018.03
研究方向
溶瘤病毒疗法与肿瘤免疫治疗
近年主持科研项目
1. 国家自然科学基金面上项目（81972605），2020/01~2023/12；
2. 国家自然科学基金青年科学基金项目（81503088），2016/01~2018/12；
3. 广东省自然科学基金-杰出青年项目（2021B1515020067），2021/01~2024/12；
4. 广州市科技计划项目-珠江科技新星专项（201906010069），2019/04~2021/03；
5.广州市科技计划-科技菁英“领航”项目（2024A04J6407），2024/04~2027/03；
6. 广东省自然科学基金-博士启动（2016A030310160），2016/06~2019/06；
7. 暨南大学优秀学术骨干项目，2019/01~2021/12；
8. 南方医科大学高层次人才引进启动基金，2024/04-2027/03.
代表性论文
1. Zhang, H.#, Li, K.#, Lin, Y.#, Xing, F., Xiao, X., Cai, J., Zhu, W., Liang, J., Tan, Y., Fu, L., Wang, F., Yin, W., Lu, B., Qiu, P., Su, X., Gong, S., Bai, X., Hu, J.*, and Yan, G.*. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Science Translational Medicine. 2017, 9(404). Highlighted in Science Translational Medicine. Comments in Nature Reviews | gastroenterology＆hepatology.
2. Chen, X.#, Liu, J.#, Li, Y.#, Zeng, Y., Wang, F., Cheng, Z., Duan, H., Pan, G., Yang, S., Chen, Y., Li, Q., Shen, X., Li, Y., Qin, Z., Chen, J., Huang, Y., Wang, X., Lu, Y., Shu, M., Zhang, Y., Wang, G., Li, K., Lin, X.*, Xing, F.*, and Zhang, H.*. IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma. Nature Communications. 2023, 14(6781).
3. Huang, Y.#, Wang, F.#, Lin, X.#, Li, Q., Lu, Y., Zhang, J., Shen, X., Tan, J., Qin, Z., Chen, J., Chen, X., Pan, G., Wang, X., Zeng, Y., Yang, S., Liu, J., Xing, F.*, Li, K.*, and Zhang, H.*. Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation. PNAS. 2023, 120 (41) e2221653120.
4. Wang, F.#, Qi, Q.#, Qin, B.#, Wang, Y., Huang, Y., Li, Q., Shen, X., Wang, X., Yang, S., Pan, G., Chen, J., Qin, Z., Chen, X., Yang, Y., Zeng, Y., Liu, J., Li, Y., Li, Y., Cheng, Z., Lin, X., Xing, F., Zhang, Y., Wang, G., Li, K.*, Jiang, Z.*, and Zhang, H.*. Targeting VCP potentiates immune checkpoint therapy for colorectal cancer. Cell Reports. 2023, 42(113318).
5. Xiao, X.#, Liang, J.#, Huang, C., Li, K., Xing, F., Zhu, W., Lin, Z., Xu, W., Wu, G., Zhang, J., Lin, X., Tan, Y., Cai, J., Hu, J., Chen, X., Huang, Y., Qin, Z., Qiu, P., Su, X., Chen, L., Lin, Y. *, Zhang, H.*, and Yan, G.*. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nature Communications. 2018, 9(1):4342.
6. Li, K. #, Zhang, J. #, Lyu H. #, Yang J. #, Wei, W., Wang, Y., Luo, H., Zhang, Y., Jiang, X., Yi, H., Wang, M., Zhang, C., Wu, K., Xiao, L., Wen, W., Xu, H., Li, G., Wan, Y., Yang, F., Yang, R., Fu, X., Qin, B., Zhou, Z. *, Zhang, H.*, Lee, M. *. CSN6-SPOP-HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation. Advanced Science. 2024
7. Qin, Z.#, Huang, Y.#, Li, Z.#, Pan, G., Zheng, L., Xiao, X., Wang, F., Chen, J., Chen, X., Lin, X., Li, K., Yan, G., Zhang, H.*, and Xing, F.*. Glioblastoma Vascular Plasticity Limits Effector T-cell Infiltration and Is Blocked by cAMP Activation. Cancer Immunology Research. 2023, 11(10):1351-1366.
8. Lin, Y. #, Zhang, H.#, Liang, J.#, Li, K., Zhu, W., Fu, L., Wang, F., Zheng, X., Shi, H., Wu, S., Xiao, X., Chen, L., Tang, L., Yan, M., Yang, X., Tan, Y., Qiu, P., Huang, Y., Yin, W., Su, X., Hu, H., Hu, J.*, and Yan, G.*. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. PNAS. 2014, 111(42): E4504-4512.
9. Li, K.#, Zhang, H.#, Qiu, J., Lin, Y., Liang, J., Xiao, X., Fu, L., Wang, F., Cai, J., Tan, Y., Zhu, W., Yin, W., Lu, B., Xing, F., Tang, L., Yan, M., Mai, J., Li, Y., Chen, W., Qiu, P., Su, X., Gao, G., Tai, P. W., Hu, J.*, and Yan, G.*. Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1. Molecular Therapy. 2016, 24(1):156-165.
10. Li, K.#, Hu, C.#, Xing, F.#, Gao, M., Liang, J., Xiao, X., Cai, J., Tan, Y., Hu, J., Zhu, W., Yin, W., Li, Y., Chen, W., Lu, B., Mai, J., Qiu, P., Su, X., Yan, G., Zhang, H.*, and Lin, Y.*. Deficiency of the IRE1alpha-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1. Journal of Virology. 2018, 92(6).
11. Tan, Y. #, Lin, Y. #, Li, K., Xiao, X., Liang, J., Cai, J., Guo, L., Li, C., Zhu, W., Xing, F., Mai, J., Gu, J., Tan, X., Yin, W., Lu, B., Qiu, P., Su, X., Gao, M., Hu, J., He, S., Lu, L., Gong, S., Yan, G., and Zhang, H.*. Selective Antagonism of Bcl-xL Potentiates M1 Oncolysis by Enhancing Mitochondrial Apoptosis. Human Gene Therapy. 2018, 29(8):950-961.
12. Zhang, H.#, Lin, Y.#, Li, K., Liang, J., Xiao, X., Cai, J., Tan, Y., Xing, F., Mai, J., Li, Y., Chen, W., Sheng, L., Gu, J., Zhu, W., Yin, W., Qiu, P., Su, X., Lu, B., Tian, X., Liu, J., Lu, W., Dou, Y., Huang, Y., Hu, B., Kang, Z., Gao, G., Mao, Z., Cheng, S. Y., Lu, L., Bai, X. T., Gong, S., Yan, G., and Hu, J.*. Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections. Human Gene Therapy. 2016, 27(9):700-711.
